Bayer, Broad Institute Extend Cardiovascular Drug Research Pact
The Pharma Data
JUNE 11, 2025
The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.
Let's personalize your content